Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
MOUNTAIN VIEW (AFX) - Pharmaceutical company Vivus Inc. said Tuesday the Food and Drug Administration will review its EvaMist product as a new treatment for hot flashes related to menopause.
Earlier this year, a late-stage study by Vivus showed EvaMist, which is sprayed on the skin, reduced the number and severity of hot flashes related to menopause.
EvaMist contains estradiol, a naturally occurring estrogen.
"We are already working with the agency and look forward to gaining regulatory approval of this important new treatment for women suffering with the symptoms of menopause," said Leland F. Wilson, Vivus president and chief executive, in a statement. Copyright 2006 Associated Press. All rights reserved. This material may not be
Copyright 2006 AFX News Limited. All Rights Reserved.
